Visby Medical appoints Mark Ibison as Chief Financial Officer, Christopher J. Jowett as Chief Commercial Officer, and Alicia Zuiker as Chief People Officer
The global COVID-19 pandemic touches and disrupts every aspect of life and livelihood across geographies. Despite progress with public health practices and vaccinations, our personal and professional futures face uncertainty. Inconsistent and ambiguous re-opening procedures hinder a robust return to pre-pandemic routines that can restore productivity and economic health.
With the COVID-19 vaccine being distributed and overall infection rates stabilizing, people are beginning to talk about life after the pandemic. Anxious to get back to some kind of normality, even if it means adopting a new normal that includes continued mask wearing and physical distancing, businesses are making plans to open back up.
Expanding critical access to the only single-use, rapid PCR test, at the point of care.
Visby Medical pairs speed with the accuracy of gold-standard PCR testing in a single-use device, so doctors don’t have to fight blind.
A study of the performance of the Visby Medical Sexual Health Test, a single-use, point-of-care PCR device.
PCR’s superpower lies in its super sensitivity, which enables it to sniff out even low levels of a pathogen in minutes. Here’s how it works.
Visby Medical, an infectious disease diagnostic company, received funding from the National Institutes of Health as part of the organization’s Rapid Acceleration of Diagnostics (RADx) program, an initiative that aims to combat SARS-CoV-2 and increase national testing capacity for COVID-19.
Personal PCR could one day become as common as the common cold. In the future, the device will deliver lab accurate results anywhere and to anyone — forever changing our relationship with diagnostics.
Seven-year-old startup emerges from stealth mode, provides adaptable and rapid testing technology to frontline lab personnel fighting the pandemic